PMID- 31540204
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20200319
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 18
DP  - 2019 Sep 13
TI  - Relevance of Surface Neuronal Protein Autoantibodies as Biomarkers in 
      Seizure-Associated Disorders.
LID - 10.3390/ijms20184529 [doi]
LID - 4529
AB  - The detection of neuronal surface protein autoantibody-related disorders has 
      contributed to several changes in our understanding of central nervous system 
      autoimmunity. The clinical presentation of these disorders may be associated (or 
      not) with tumors, and often patients develop an inexplicable onset of epilepsy, 
      catatonic or autistic features, or memory and cognitive dysfunctions. The 
      autoantigens in such cases have critical roles in synaptic transmission and 
      plasticity, memory function, and process learning. For months, patients with such 
      antibodies may be comatose or encephalopathic and yet completely recover with 
      palliative care and immunotherapies. This paper reviews several targets of 
      neuronal antibodies as biomarkers in seizure disorders, focusing mainly on 
      autoantibodies, which target the extracellular domains of membrane proteins, 
      namely leucine-rich glioma-inactivated-1 (LGI1), contactin-associated 
      protein-like 2 (CASPR2), the N-methyl-D-aspartate receptor (NMDAR), 
      gamma-aminobutyric acid receptor-B (GABA(B)R), the glycine receptor (GlyR), and 
      a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). In order 
      to restore health status, limit hospitalization, and optimize results, testing 
      these antibodies should be done locally, using internationally certified 
      procedures for a precise and rapid diagnosis, with the possibility of initiating 
      therapy as soon as possible.
FAU - Stanciu, Gabriela Dumitrita
AU  - Stanciu GD
AUID- ORCID: 0000-0003-4440-9628
AD  - Grigore T. Popa University of Medicine and Pharmacy, Center for Advanced Research 
      and Development in Experimental Medicine (CEMEX), 16 Universitatii street, Iasi 
      700115, Romania. gabriela-dumitrita.s@umfiasi.ro.
FAU - Bild, Veronica
AU  - Bild V
AD  - Grigore T. Popa University of Medicine and Pharmacy, Center for Advanced Research 
      and Development in Experimental Medicine (CEMEX), 16 Universitatii street, Iasi 
      700115, Romania. veronica.bild@gmail.com.
AD  - Grigore T. Popa University of Medicine and Pharmacy, Pharmacodynamics and 
      Clinical Pharmacy Department, 16 Universitatii street, Iasi 700115, Romania. 
      veronica.bild@gmail.com.
FAU - Ababei, Daniela Carmen
AU  - Ababei DC
AD  - Grigore T. Popa University of Medicine and Pharmacy, Pharmacodynamics and 
      Clinical Pharmacy Department, 16 Universitatii street, Iasi 700115, Romania. 
      dana.ababei@gmail.com.
FAU - Rusu, Razvan Nicolae
AU  - Rusu RN
AD  - Grigore T. Popa University of Medicine and Pharmacy, Pharmacodynamics and 
      Clinical Pharmacy Department, 16 Universitatii street, Iasi 700115, Romania. 
      razvan.nicolae.rusu@gmail.com.
FAU - Beschea Chiriac, Sorin Ioan
AU  - Beschea Chiriac SI
AD  - University of Agricultural Sciences and Veterinary Medicine "Ion Ionescu de la 
      Brad", Faculty of Veterinary Medicine, 8 M. Sadoveanu Alley, Iasi 700489, 
      Romania. sbeschea@yahoo.com.
FAU - Rezus, Elena
AU  - Rezus E
AD  - Grigore T. Popa University of Medicine and Pharmacy, Department of Rheumatology 
      and Physiotherapy, 16 Universitatii Street, Iasi 700115, Romania. 
      elena.rezus@umfiasi.ro.
FAU - Luca, Andrei
AU  - Luca A
AUID- ORCID: 0000-0002-3628-4637
AD  - Grigore T. Popa University of Medicine and Pharmacy, Center for Advanced Research 
      and Development in Experimental Medicine (CEMEX), 16 Universitatii street, Iasi 
      700115, Romania. andrei.g.luca@umfiasi.ro.
AD  - Grigore T. Popa University of Medicine and Pharmacy, Pneumology Department, 16 
      Universitatii Street, Iasi 700115, Romania. andrei.g.luca@umfiasi.ro.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190913
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Nerve Tissue Proteins)
SB  - IM
MH  - Autoantibodies/*metabolism
MH  - Biomarkers/metabolism
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - Immunomodulation
MH  - Male
MH  - Nerve Tissue Proteins/*immunology
MH  - Seizures/*diagnosis/immunology/therapy
PMC - PMC6769659
OTO - NOTNLM
OT  - autoantibodies
OT  - biomarkers
OT  - diagnostic
OT  - immunomodulatory therapy
OT  - neuronal surface proteins
OT  - seizure disorders
COIS- The authors declare no conflicts of interest.
EDAT- 2019/09/22 06:00
MHDA- 2020/02/11 06:00
PMCR- 2019/09/01
CRDT- 2019/09/22 06:00
PHST- 2019/08/05 00:00 [received]
PHST- 2019/09/10 00:00 [revised]
PHST- 2019/09/12 00:00 [accepted]
PHST- 2019/09/22 06:00 [entrez]
PHST- 2019/09/22 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - ijms20184529 [pii]
AID - ijms-20-04529 [pii]
AID - 10.3390/ijms20184529 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Sep 13;20(18):4529. doi: 10.3390/ijms20184529.